CAS 2765082-12-8

Formule : C47H60N8O6S

InChI : InChI=1S/C47H60N8O6S/c1-6-54-39-12-9-28-18-31(39)33(43(54)32-19-30(22-48-42(32)27(2)59-5)53-16-14-52(15-17-53)29-10-11-29)21-47(3,4)26-61-46(58)36-8-7-13-55(51-36)45(57)37(20-40-49-38(28)25-62-40)50-44(56)41-34-23-60-24-35(34)41/h9,12,18-19,22,25,27,29,34-37,41,51H,6-8,10-11,13-17,20-21,23-24,26H2,1-5H3,(H,50,56)/t27-,34-,35+,36-,37-,41?/m0/s1

Code InChI : NBLZKEHVVJSAAY-UDSCPAMHSA-N

SMILES : CCN1C2=C3C=C(C=C2)C4=CSC(=N4)C[C@@H](C(=O)N5CCC[C@H](N5)C(=O)OCC(CC3=C1C6=C(N=CC(=C6)N7CCN(CC7)C8CC8)[C@H](C)OC)(C)C)NC(=O)C9[C@H]1[C@@H]9COC1

RMC-7977

CAS : 2765082-12-8

RMC-7977 is a inhibitor of the active (GTP-bound) forms of KRAS, HRAS, and NRAS with anticancer activity for the study of solid tumors with KRAS G12C mutations.

Formule : C₄₇H₆₀N₈O₆S

Degré de pureté : 97.11% - 99.86%

Couleur et forme : Solid

Masse moléculaire : 865.09

Ref: TM-T81263

RMC-7977

CAS : 2765082-12-8

RMC-7977

Formule : C₄₇H₆₀N₈O₆S

Degré de pureté : 99.5%

Masse moléculaire : 865.114

Ref: 54-BUP11451

(1Α,5Α,6Α)-N-[(2R,14S,18S)-2-[5-(4-Cyclopropyl-1-Piperazinyl)-2-[(1S)-1-Methoxyethyl]-3-Pyridinyl]-1-Ethyl-18,19,20,21-Tetrahydro-25,25-Dimethyl-15,22-Dioxo-17H-5,3-([4,2]-Endo-Thiazolopropano[1,3]-Endo-Pyridazinomethanoxypropano)-1H-Indol-14-Yl]-3-Oxabic

CAS : 2765082-12-8

Degré de pureté : 98%

Ref: IN-DA02C4SK

RMC-7977

CAS : 2765082-12-8

(1α,5α,6α)-N-[(2R,14S,18S)-2-[5-(4-Cyclopropyl-1-piperazinyl)-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-1-ethyl-18,19,20,21-tetrahydro-25,25-dimethyl-15,22-dioxo-17H-5,3-([4,2]-endo-thiazolopropano[1,3]-endo-pyridazinomethanoxypropano)-1H-indol-14-yl]-3-oxabicyclo[3.1.0]hexane-6-carboxamide

Formule : C₄₇H₆₀N₈O₆S

Degré de pureté : 98%

Masse moléculaire : 865.09

Ref: IN-DG02525391

RMC-7977

CAS : 2765082-12-8

Formule : C₄₇H₆₀N₈O₆S

Masse moléculaire : 865.11

Ref: 4Z-R-191001